STOCK TITAN

[Form 4] Sight Sciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

David Badawi, Chief Technology Officer and director of Sight Sciences, Inc. (SGHT), reported a sale of 6,033 shares of common stock on 10/03/2025 at a price of $3.27 per share. The filing states the shares were sold to cover the reporting person's tax liability from the vesting of restricted stock units. After the sale, Mr. Badawi beneficially owned 1,864,992 shares of common stock.

David Badawi, Chief Technology Officer e direttore di Sight Sciences, Inc. (SGHT), ha riportato una vendita di 6.033 azioni ordinarie in data 10/03/2025 al prezzo di $3,27 per azione. La dichiarazione afferma che le azioni sono state vendute per coprire l'imposta del dichiarante derivante dal vesting di unità azionarie soggette a restrizioni. Dopo la vendita, il signor Badawi deteneva beneficamente 1.864.992 azioni ordinarie.

David Badawi, Director de Tecnología y miembro del consejo de Sight Sciences, Inc. (SGHT), informó de la venta de 6,033 acciones ordinarias en 03/10/2025 a un precio de $3,27 por acción. El documento indica que las acciones se vendieron para cubrir la obligación tributaria de la persona que reporta derivada del vesting de unidades de acciones restringidas. Después de la venta, el Sr. Badawi poseía beneficiosamente 1,864,992 acciones ordinarias.

David Badawi, Sight Sciences, Inc. (SGHT)의 최고 기술 책임자(CTO) 겸 이사는 2025-10-03에 보통주 6,033주를 $3.27에 매도했다고 보고했습니다. 보고서에 따르면 해당 주식은 제한 주식 단위의 vesting으로 인한 신고자의 세금 부담을 충당하기 위해 매도되었습니다. 매도 후 Badawi 씨는 보통주를 1,864,992주 유익하게 소유하고 있었습니다.

David Badawi, Directeur technique et administrateur de Sight Sciences, Inc. (SGHT), a annoncé la vente de 6 033 actions ordinaires le 03/10/2025 au prix par action de $3,27. Le dossier indique que les actions ont été vendues pour couvrir l'impôt sur le revenu du déclarant provenant de l'acquisition d'unités d'actions restreintes. Après la vente, M. Badawi détenait de manière bénéficiaire 1 864 992 actions ordinaires.

David Badawi, Chief Technology Officer und Director von Sight Sciences, Inc. (SGHT), meldete den Verkauf von 6.033 Stammaktien am 03.10.2025 zu einem Preis von $3,27 pro Aktie. Die Einreichung gibt an, dass die Aktien verkauft wurden, um die Steuerverbindlichkeit der meldenden Person aus dem Vesting der Restricted Stock Units zu decken. Nach dem Verkauf besaß Herr Badawi benefizient 1.864.992 Stammaktien.

David Badawi، رئيس قسم التقنية وعضو مجلس إدارة Sight Sciences, Inc. (SGHT)، أبلغ عن بيع 6,033 سهماً من الأسهم العادية في 03/10/2025 بسعر $3.27 للسهم. ينص التقرير إلى أن الأسهم بيعت لتغطية الالتزام الضريبي للشخص المبلغ عنه الناتج عن vesting وحدات الأسهم المقيدة. بعد البيع، كان السيد Badawi يمتلك فعلياً 1,864,992 سهماً من الأسهم العادية.

David BadawiSight Sciences, Inc. (SGHT) 的首席技术官兼董事在2025-10-03以每股$3.27的价格出售了6,033股普通股。该披露文件称,为了覆盖报告人因受限股票单位归属而产生的税务负担,出售了这些股票。出售后,Badawi先生实益拥有1,864,992股普通股。

Positive
  • None.
Negative
  • None.

David Badawi, Chief Technology Officer e direttore di Sight Sciences, Inc. (SGHT), ha riportato una vendita di 6.033 azioni ordinarie in data 10/03/2025 al prezzo di $3,27 per azione. La dichiarazione afferma che le azioni sono state vendute per coprire l'imposta del dichiarante derivante dal vesting di unità azionarie soggette a restrizioni. Dopo la vendita, il signor Badawi deteneva beneficamente 1.864.992 azioni ordinarie.

David Badawi, Director de Tecnología y miembro del consejo de Sight Sciences, Inc. (SGHT), informó de la venta de 6,033 acciones ordinarias en 03/10/2025 a un precio de $3,27 por acción. El documento indica que las acciones se vendieron para cubrir la obligación tributaria de la persona que reporta derivada del vesting de unidades de acciones restringidas. Después de la venta, el Sr. Badawi poseía beneficiosamente 1,864,992 acciones ordinarias.

David Badawi, Sight Sciences, Inc. (SGHT)의 최고 기술 책임자(CTO) 겸 이사는 2025-10-03에 보통주 6,033주를 $3.27에 매도했다고 보고했습니다. 보고서에 따르면 해당 주식은 제한 주식 단위의 vesting으로 인한 신고자의 세금 부담을 충당하기 위해 매도되었습니다. 매도 후 Badawi 씨는 보통주를 1,864,992주 유익하게 소유하고 있었습니다.

David Badawi, Directeur technique et administrateur de Sight Sciences, Inc. (SGHT), a annoncé la vente de 6 033 actions ordinaires le 03/10/2025 au prix par action de $3,27. Le dossier indique que les actions ont été vendues pour couvrir l'impôt sur le revenu du déclarant provenant de l'acquisition d'unités d'actions restreintes. Après la vente, M. Badawi détenait de manière bénéficiaire 1 864 992 actions ordinaires.

David Badawi, Chief Technology Officer und Director von Sight Sciences, Inc. (SGHT), meldete den Verkauf von 6.033 Stammaktien am 03.10.2025 zu einem Preis von $3,27 pro Aktie. Die Einreichung gibt an, dass die Aktien verkauft wurden, um die Steuerverbindlichkeit der meldenden Person aus dem Vesting der Restricted Stock Units zu decken. Nach dem Verkauf besaß Herr Badawi benefizient 1.864.992 Stammaktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Badawi David

(Last) (First) (Middle)
C/O SIGHT SCIENCES, INC.
4040 CAMPBELL AVE., SUITE 100

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Technology Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/03/2025 S 6,033(1) D $3.27 1,864,992 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.
/s/Jeremy Hayden, Attorney-in-Fact for David Badawi 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did David Badawi (SGHT) report on Form 4?

The Form 4 reports a sale of 6,033 shares on 10/03/2025 at $3.27 per share to cover tax withholding related to vested restricted stock units.

How many shares does David Badawi beneficially own after the transaction?

The filing shows Mr. Badawi beneficially owned 1,864,992 shares of Sight Sciences common stock following the reported sale.

What roles does the reporting person hold at SGHT?

The reporting person, David Badawi, is listed as both a Director and the company's Chief Technology Officer.

Why were the shares sold according to the Form 4?

The sale was made to cover the reporting person's tax liability arising from the vesting of restricted stock units, as stated in the explanation.

When was the Form 4 signed and by whom?

The Form 4 is signed on behalf of the reporting person by Jeremy Hayden, Attorney-in-Fact and dated 10/03/2025.
Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Latest News

SGHT Latest SEC Filings

SGHT Stock Data

175.95M
41.48M
20.66%
50.37%
1.99%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MENLO PARK